SuperworthVertex Pharmaceuticals profit margin VRTX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 35.0%
- Operating margin, 12 months
- 38.0%
- Net margin on a year earlier
- +3.1 pts
- Peer median
- 26.3%
Over the twelve months to Jun 30, 2026, Vertex Pharmaceuticals kept 35.0% of its revenue as net profit, with an operating margin of 38.0% and a gross margin of 86.0%.
Five years earlier its net margin was 29.8%.
The median for 8 biotech stocks of a similar size is 26.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 32.9% | 34.8% | 86.2% |
| FY2024 | −4.9% | −2.1% | 86.1% |
| FY2023 | 36.7% | 38.8% | 87.2% |
| FY2022 | 37.2% | 48.2% | 87.9% |
| FY2021 | 30.9% | 36.7% | 88.1% |
| FY2020 | 43.7% | 46.0% | 88.1% |
| FY2019 | 28.3% | 28.8% | 86.8% |
| FY2018 | 68.8% | 20.8% | 86.6% |
| FY2017 | 10.6% | 5.0% | 88.9% |
| FY2016 | −6.6% | 0.6% | 87.6% |
| FY2015 | −53.9% | −45.2% | 87.9% |
| FY2014 | n/a | n/a | 89.5% |
| FY2013 | −36.7% | −50.3% | 89.3% |
| FY2012 | −7.0% | 0.2% | 81.7% |
| FY2011 | 2.1% | 8.1% | 94.3% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 35.0% | +3.1 pts | 38.0% | |
| Q1 FY26 | 35.5% | +44.4 pts | 38.3% | |
| Q4 FY25 | 32.9% | +37.8 pts | 34.8% | |
| Q3 FY25 | 31.3% | +35.9 pts | 34.1% | |
| Q2 FY25 | 31.9% | +36.6 pts | 34.4% | |
| Q1 FY25 | −8.9% | −48.4 pts | −6.7% | |
| Q4 FY24 | −4.9% | −41.5 pts | −2.1% | |
| Q3 FY24 | −4.5% | −40.5 pts | −2.5% | |
| Q2 FY24 | −4.7% | −40.1 pts | −3.4% | |
| Q1 FY24 | 39.5% | +4.1 pts | 41.2% | |
| Q4 FY23 | 36.7% | −0.5 pts | 38.8% | |
| Q3 FY23 | 35.9% | −1.7 pts | 40.2% |
Against its peers
Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| VRTXVertex Pharmaceuticals | 35.0% |
| REGNRegeneron Pharmaceuticals | 27.9% |
| ONCBeOne Medicines | 10.7% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| UTHRUnited Therapeutics | 41.6% |
| INCYIncyte | 27.7% |
| EXELExelixis | 35.3% |
| NBIXNeurocrine Biosciences | 20.9% |
| HALOHalozyme Therapeutics | 24.9% |
| Peer median | 26.3% |
Where Vertex Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Vertex Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.